Vedolizumab in the treatment of Crohn's disease;Vedolizumab en el tratamiento de la enfermedad de Crohn

Gastroenterologia y Hepatologia

Volumn 38, Issue 5, 2015, Pages 338-348

  Gisbert, Javier P ^a   Domènech, Eugeni ^b  

^a Instituto de Investigación Sanitaria del Hospital Universitario de La Princesa   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Anti TNF; Crohn's disease; Vedolizumab

Indexed keywords

VEDOLIZUMAB; ADALIMUMAB; GASTROINTESTINAL AGENT; IMMUNOGLOBULIN; INFLIXIMAB; INTEGRIN; INTEGRIN ALPHA4BETA7; MADCAM1 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; MUCOPROTEIN; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

ARTICLE; CROHN DISEASE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; HUMAN; SMALL INTESTINE; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; METABOLISM; T LYMPHOCYTE; TREATMENT OUTCOME;

ADALIMUMAB; ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOGLOBULINS; INFLIXIMAB; INTEGRINS; MUCOPROTEINS; T-LYMPHOCYTES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84927956527     PISSN: 02105705     EISSN: 15789519     Source Type: Journal    
DOI: 10.1016/j.gastrohep.2014.12.003     Document Type: Article

References (67)

1. Gisbert J.P., Gomollon F., Mate J., Pajares J.M. Questions and answers on the role of azathioprine and 6-mercaptopurine in the treatment of inflammatory bowel disease. Gastroenterol Hepatol. 2002, 25:401-415.
2. Chaparro M., Ordas I., Cabre E., Garcia-Sanchez V., Bastida G., Penalva M., et al. Safety of thiopurine therapy in inflammatory bowel disease: Long-term follow-up study of 3931 patients. Inflamm Bowel Dis. 2013, 19:1404-1410.
3. Gonzalez-Lama Y., Taxonera C., Lopez-Sanroman A., Perez-Calle J.L., Bermejo F., Pajares R., et al. Methotrexate in inflammatory bowel disease: A multicenter retrospective study focused on long-term efficacy and safety. The Madrid experience. Eur J Gastroenterol Hepatol. 2012, 24:1086-1091.
4. Gomollon F., Rubio S., Charro M., Muñoz F., Garcia S., Gisbert J.P., et al. Reccomendations of the Spanish Working Group on Crohn's disease and ulcerative colitis (GETECCU) on the use of methotrexate in inflammatory bowel diseases. Gastroenterol Hepatol. 2014, pii: S0210-5705(14)00264-7.
5. Domenech E., Manosa M., Navarro M., Masnou H., Garcia-Planella E., Zabana Y., et al. Long-term methotrexate for Crohn's disease: Safety and efficacy in clinical practice. J Clin Gastroenterol. 2008, 42:395-399.
6. Cabriada J.L., Vera I., Domenech E., Barreiro-de Acosta M., Esteve M., Gisbert J.P., et al. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on the use of anti-tumor necrosis factor drugs in inflammatory bowel disease. Gastroenterol Hepatol. 2013, 36:127-146.
7. Ben-Horin S., Chowers Y. Review article: Loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther. 2011, 33:987-995.
8. Cohen L.B., Nanau R.M., Delzor F., Neuman M.G. Biologic therapies in inflammatory bowel disease. Transl Res. 2014.
9. Ford A.C., Sandborn W.J., Khan K.J., Hanauer S.B., Talley N.J., Moayyedi P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011, 106:644-659. quiz 60.
10. Chaparro M., Martinez-Montiel P., van Domselaar M., Bermejo F., Perez-Calle J.L., Casis B., et al. Intensification of infliximab therapy in Crohn's disease: Efficacy and safety. J Crohns Colitis. 2012, 6:62-67.
11. Chaparro M., Panes J., Garcia V., Manosa M., Esteve M., Merino O., et al. Long-term durability of infliximab treatment in Crohn's disease and efficacy of dose escalation in patients losing response. J Clin Gastroenterol. 2011, 45:113-118.
12. Colombel J.F., Sandborn W.J., Rutgeerts P., Kamm M.A., Yu A.P., Wu E.Q., et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: Results from the CHARM trial. Am J Gastroenterol. 2009, 104:1170-1179.
13. Gisbert J.P., Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: A review. Am J Gastroenterol. 2009, 104:760-767.
14. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., et al. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet. 2002, 359:1541-1549.
15. Krishnareddy S., Swaminath A. When combination therapy isn't working: Emerging therapies for the management of inflammatory bowel disease. World J Gastroenterol. 2014, 20:1139-1146.
16. Allen P.B., Peyrin-Biroulet L. Moving towards disease modification in inflammatory bowel disease therapy. Curr Opin Gastroenterol. 2013, 29:397-404.
17. Chaparro M. New advances in the treatment of inflammatory bowel disease. Gastroenterol Hepatol. 2013, 36(Suppl 2):21-29.
18. Lowenberg M., D'Haens G. Novel targets for inflammatory bowel disease therapeutics. Curr Gastroenterol Rep. 2013, 15:311.
19. Mozaffari S., Nikfar S., Abdolghaffari A.H., Abdollahi M. New biologic therapeutics for ulcerative colitis and Crohn's disease. Expert Opin Biol Ther. 2014, 14:583-600.
20. Reenaers C., Louis E., Belaiche J. Current directions of biologic therapies in inflammatory bowel disease. Therap Adv Gastroenterol. 2010, 3:99-106.
21. Rietdijk S.T., D'Haens G.R. Recent developments in the treatment of inflammatory bowel disease. J Dig Dis. 2013, 14:282-287.
22. Sandborn W.J. The future of inflammatory bowel disease therapy: Where do we go from here?. Dig Dis. 2012, 30(Suppl 3):140-144.
23. Cominelli F. Inhibition of leukocyte trafficking in inflammatory bowel disease. N Engl J Med. 2013, 369:775-776.
24. Fiorino G., Correale C., Fries W., Repici A., Malesci A., Danese S. Leukocyte traffic control: A novel therapeutic strategy for inflammatory bowel disease. Expert Rev Clin Immunol. 2010, 6:567-572.
25. Ghosh N., Chaki R., Mandal S.C. Inhibition of selective adhesion molecules in treatment of inflammatory bowel disease. Int Rev Immunol. 2012, 31:410-427.
26. Lobaton T., Vermeire S., van Assche G., Rutgeerts P. Review article: Anti-adhesion therapies for inflammatory bowel disease. Aliment Pharmacol Ther. 2014, 39:579-594.
27. McLean L.P., Shea-Donohue T., Cross R.K. Vedolizumab for the treatment of ulcerative colitis and Crohn's disease. Immunotherapy. 2012, 4:883-898.
28. Mosli M.H., Rivera-Nieves J., Feagan B.G. T-cell trafficking and anti-adhesion strategies in inflammatory bowel disease: Current and future prospects. Drugs. 2014, 74:297-311.
29. Thomas S., Baumgart D.C. Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis. Inflammopharmacology. 2012, 20:1-18.
30. Tilg H., Kaser A. Vedolizumab, a humanized mAb against the alpha4beta7 integrin for the potential treatment of ulcerative colitis and Crohn's disease. Curr Opin Investig Drugs. 2010, 11:1295-1304.
31. Kempster S.L., Kaser A. alpha4beta7 integrin: Beyond T cell trafficking. Gut. 2014, 63:1377-1379.
32. Targan S.R., Feagan B.G., Fedorak R.N., Lashner B.A., Panaccione R., Present D.H., et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology. 2007, 132:1672-1683.
33. Targan S.R., Hanauer S.B., van Deventer S.J., Mayer L., Present D.H., Braakman T., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997, 337:1029-1035.
34. Fedyk E.R., Wyant T., Yang L.L., Csizmadia V., Burke K., Yang H., et al. Exclusive antagonism of the alpha4 beta7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates. Inflamm Bowel Dis. 2012, 18:2107-2119.
35. Rezaie A. Vedolizumab, a gut-specific monoclonal antibody, renews hope for an alternative to anti-TNF therapy in inflammatory bowel diseases. Ann Gastroenterol. 2014, 27:179-180.
36. Wyant T., Yang L., Fedyk E. In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes. MAbs. 2013, 5:842-850.
37. Gerner R.R., Moschen A.R., Tilg H., Targeting T. B lymphocytes in inflammatory bowel diseases: Lessons from clinical trials. Dig Dis. 2013, 31(3-4):328-335.
38. Herrlinger K.R., Stange E.F., Fellermann K. Therapeutic peptides in inflammatory bowel disease. Expert Opin Biol Ther. 2014.
39. Poole R.M. Vedolizumab: First global approval. Drugs. 2014, 74:1293-1303.
40. Rosario M., Dirks N., Gastonguay M., Fox I., Milton A. Population pharmacokinetic modelling of vedolizumab in patients with ulcerative colitis or Crohn's disease. J Crohns Colitis. 2014, 8(suppl.1):S225.
41. Milch C., Wyant T., Xu J., Parikh A., Kent W., Fox I., et al. Vedolizumab, a monoclonal antibody to the gut homing alpha4beta7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype. J Neuroimmunol. 2013, 264(1-2):123-126.
42. Dirks N.L., Rosario M., Gastonguay M.R., Fox I., Milton A. Population pharmacokinetic modeling of vedolizumab in patients with ulcerative colitis or Crohn's disease. Gastroenterology. 2014, 146. S-S591.
43. Parikh A., Leach T., Wyant T., Scholz C., Sankoh S., Mould D.R., et al. Vedolizumab for the treatment of active ulcerative colitis: A randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis. 2012, 18:1470-1479.
44. Jovani M., Danese S. Vedolizumab for the treatment of IBD: A selective therapeutic approach targeting pathogenic a4b7 cells. Curr Drug Targets. 2013, 14:1433-1443.
45. Wang C., McDonald K., Hanly E., Newberry R.D. The effect of α4β7 blockade on lymphocyte trafficking in the acute injury colitis model. Gastroenterology. 2009, 136:A-A405.
46. Vedolizumab Ficha técnica. [consultado 15 Oct 2014]. Disponible en: . http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/002782/WC500168528.pdf.
47. Sands B.E., Dubinsky M.C., Vermeire S., Sankoh S.M.R., Milch C. Effects of increased vedolizumab dosing frequency on disease activity in ulcerative colitis and Crohn's disease. United European Gastroenterology Journal 2014, 2(S1):A67.
48. Sandborn W.J., Feagan B.G., Rutgeerts P., Hanauer S., Colombel J.F., Sands B.E., et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013, 369:711-721.
49. Sands B.E., Feagan B.G., Rutgeerts P., Colombel J.F., Sandborn W.J., Sy R., et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014, 147:618-627. e3.
50. Parikh A., Fox I., Leach T., Xu J., Scholz C., Patella M., et al. Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013, 19:1691-1699.
51. Hanauer H., Rutgeerts P., Xu J., Rubin D.T., Smyth M., Abhyankar B. Long-term efficacy of vedolizumab therapy for Crohn's disease. United European Gastroenterology Journal 2014, 2(1S):A66.
52. Hanauer S.B., Feagan B.G., Macintosh D.G., Xu J., Milch C., Fox I., et al. Efficacy of vedolizumab in Crohn's disease by prior treatment failure in Gemini II, a randomized, placebo-controlled, double-blind, multicenter study. Gastroenterology. 2013, 144. S-S772.
53. Sandborn W.J., Feagan B.G., Reinisch W., Smyth M.D., Xu J., Parikh A., et al. Effects of continued vedolizumab therapy for Crohn's disease in week 6 induction therapy nonresponders. Gastroenterology. 2014, 146. S-S588.
54. Sandborn W.J., Feagan B., Reinisch W., Smyth M., Xu J., Parikh A., et al. Efficacy of continued vedolizumab therapy in patients with Crohn's disease who did not respond to vedolizumab induction therapy at week 6. J Crohns Colitis 2014, 8(I (suppl.1)):S274-S275.
55. Feagan B.G., Rutgeerts P., Sands B.E., Hanauer S., Colombel J.F., Sandborn W.J., et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013, 369:699-710.
56. Colombel J-F., Sands B.E., Feagan B.G., Loftus E.V., Sankoh S., Fox I., et al. Integrated safety analysis of vedolizumab for the treatment of ulcerative colitis or Crohn's disease. Gastroenterology. 2013, 144. S-S113.
57. Colombel J.F., Sands B., Hanauer S., Rutgeerts P., Sandborn W., Danese S., et al. Long-term safety of vedolizumab for the treatment of ulcerative colitis or Crohn's disease. Am J Gastroenterol. 2013, 108(Suppl.1):S502.
58. Colombel J.F., Siegel C.A., Abhyankar B., Loftus E.V., Lewis J.D., Sankoh S., et al. Safety of vedolizumab alone or with concomitant corticosteroids and/or immunosuppressants in patients with ulcerative colitis or Crohn's disease. United European Gastroenterology Journal 2014, 2(1S):A82.
59. Govani S.M., Waljee A.K., Higgins P.D. Anti-adhesion therapies and the rule of 3 for rare events. Am J Gastroenterol. 2013, 108:1831-1832.
60. Haanstra K.G., Hofman S.O., Lopes Estevao D.M., Blezer E.L., Bauer J., Yang L.L., et al. Antagonizing the alpha4beta1 integrin, but not alpha4beta7, inhibits leukocytic infiltration of the central nervous system in rhesus monkey experimental autoimmune encephalomyelitis. J Immunol. 2013, 190:1961-1973.
61. Herold T.R., Jakl V., Graser A., Eibl-Lindner K. Hemianopia and visual loss due to progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis. Clin Ophthalmol. 2012, 6:1131-1133.
62. Cordioli C., De Rossi N., Rasia S., Lodoli G., Capra R. Early detection and favourable outcome of natalizumab-related progressive multifocal leukoencephalopathy (PML) in two multiple sclerosis patients. Neurol Sci. 2014, 1-3.
63. Parikh A., Fedyk E., Soler D., Wyant T., Kadambi V., Leach T., et al. Gastrointestinal selectivity of vedolizumab (MLN0002), a humanized monoclonal antibody to α 4β 7 integrin. J Crohn Colitis. 2009, 3:S62.
64. Fedyk E.R., Csizmadia V., Shyu W., Yang L., Wyant T., Estevao D., et al. The gastrointestinal-selective biologic vedolizumab does not impair immune surveillance of the central nervous system in non-human primates. J Crohns Colitis 2011, 5:S1-S192.
65. Feagan B.G., Greenberg G.R., Wild G., Fedorak R.N., Pare P., McDonald J.W., et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol. 2008, 6:1370-1377.
66. Gisbert J.P., Marín A.C., McNicholl A.G., Chaparro M. Systematic review with Meta-analysis: the efcacy of a second anti-TNF in patients with inammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther. 2015, En prensa.
67. Gisbert J.P., Chaparro M. Use of a third anti-TNF after failure of two previous anti-TNFs in patients with inflammatory bowel disease: is it worth it?. Scand J Gastroenterol. 2015, En prensa.